These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1729 related articles for article (PubMed ID: 25901682)

  • 1. Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
    Kreiter S; Vormehr M; van de Roemer N; Diken M; Löwer M; Diekmann J; Boegel S; Schrörs B; Vascotto F; Castle JC; Tadmor AD; Schoenberger SP; Huber C; Türeci Ö; Sahin U
    Nature; 2015 Apr; 520(7549):692-6. PubMed ID: 25901682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
    Sahin U; Derhovanessian E; Miller M; Kloke BP; Simon P; Löwer M; Bukur V; Tadmor AD; Luxemburger U; Schrörs B; Omokoko T; Vormehr M; Albrecht C; Paruzynski A; Kuhn AN; Buck J; Heesch S; Schreeb KH; Müller F; Ortseifer I; Vogler I; Godehardt E; Attig S; Rae R; Breitkreuz A; Tolliver C; Suchan M; Martic G; Hohberger A; Sorn P; Diekmann J; Ciesla J; Waksmann O; Brück AK; Witt M; Zillgen M; Rothermel A; Kasemann B; Langer D; Bolte S; Diken M; Kreiter S; Nemecek R; Gebhardt C; Grabbe S; Höller C; Utikal J; Huber C; Loquai C; Türeci Ö
    Nature; 2017 Jul; 547(7662):222-226. PubMed ID: 28678784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
    Xu M; Kallinteris NL; von Hofe E
    Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
    Dolan BP; Gibbs KD; Ostrand-Rosenberg S
    J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
    Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
    Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immunotherapy: exploiting neoepitopes.
    Platten M; Offringa R
    Cell Res; 2015 Aug; 25(8):887-8. PubMed ID: 26032267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.
    Yadav M; Jhunjhunwala S; Phung QT; Lupardus P; Tanguay J; Bumbaca S; Franci C; Cheung TK; Fritsche J; Weinschenk T; Modrusan Z; Mellman I; Lill JR; Delamarre L
    Nature; 2014 Nov; 515(7528):572-6. PubMed ID: 25428506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting the mutanome for tumor vaccination.
    Castle JC; Kreiter S; Diekmann J; Löwer M; van de Roemer N; de Graaf J; Selmi A; Diken M; Boegel S; Paret C; Koslowski M; Kuhn AN; Britten CM; Huber C; Türeci O; Sahin U
    Cancer Res; 2012 Mar; 72(5):1081-91. PubMed ID: 22237626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
    Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S; Komita H; Sagawa Y; Ohno T; Toda G
    Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metadherin peptides containing CD4(+) and CD8(+) T cell epitopes as a therapeutic vaccine candidate against cancer.
    Dhiman G; Lohia N; Jain S; Baranwal M
    Microbiol Immunol; 2016 Sep; 60(9):646-52. PubMed ID: 27554419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep.
    Rojas JM; Rodríguez-Calvo T; Peña L; Sevilla N
    Vaccine; 2011 Sep; 29(40):6848-57. PubMed ID: 21807057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of MHC class II-restricted tumor antigens recognized by CD4+ T cells.
    Wang RF
    Methods; 2003 Mar; 29(3):227-35. PubMed ID: 12725788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bioinformatics tool for epitope-based vaccine design that accounts for human ethnic diversity: application to emerging infectious diseases.
    Oyarzun P; Ellis JJ; Gonzalez-Galarza FF; Jones AR; Middleton D; Boden M; Kobe B
    Vaccine; 2015 Mar; 33(10):1267-73. PubMed ID: 25629524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.
    Bonehill A; Heirman C; Thielemans K
    J Gene Med; 2005 Jun; 7(6):686-95. PubMed ID: 15693037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 87.